German biotech held steady in 2025 but faces ongoing financing pressures, according to EY-Parthenon and BIO Deutschland. Total capital fell 5% to €1.8 billion, with venture...
The biotech industry thrived during the pandemic, fueled by vaccine demand, but post-2022 saw capital declines. In 2024, capital increases reached €999 million, led by Qiagen...
German biotech financing surged 78% in 2024, totalling €1.92 billion, driven by venture capital (€898 million), public market funding (€999 million), and an IPO. Notable deals...